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Abstract There is an opportunity to improve outcomes
for ovarian cancer (OC) through advances in risk stratifi-
cation, early detection and diagnosis. A population-based
OC genetic risk prediction and stratification program is
being developed. A previous focus group study with indi-
viduals from the general population showed support for the
proposed program. This qualitative interview study
explores the attitudes of women at high risk of OC. Eight
women participated in one-on-one, in-depth, semi-struc-
tured interviews to explore: experiences of learning of OC
risk, risk perceptions, OC knowledge and awareness, and
opinions on risk stratification approach. There was evi-
dence of strong support for the proposed program. Benefits
were seen as providing reassurance to women at low risk,
and reducing worry in women at high risk through appro-
priate clinical management. Stratification into ‘low’ and
‘high’ risk groups was well-received. Participants were
more hesitant about stratification to the ‘intermediate’ risk
group. The data suggest formats to effectively communi-
cate OC risk estimates will require careful thought. Inter-
actions with GPs were highlighted as a barrier to OC risk
assessment and diagnosis. These results are encouraging
for the possible introduction and uptake of a risk prediction
and stratification program for OC in the general population.
Keywords Ovarian cancer  Risk prediction  Risk
stratification  Genetic testing  High risk  BRCA1/2
Introduction
Ovarian cancer (OC) is the fifth most common cancer
amongst women in the UK, and accounts for more deaths
than all other gynaecological cancers combined despite a
relatively rare age-standardised incidence of 17 cases per
100,000 females [1]. Early stage symptoms are few and
non-specific, for example bloating and abdominal pain, and
OC is often diagnosed at an advanced stage. Despite pro-
gress in surgical techniques and chemotherapeutic agents,
5-year survival rates remain low at around 40 % [2].
Current screening strategies for OC, including trans-
vaginal ultrasound to visualise the ovaries and/or testing
for biomarkers such as CA125, have not been successful in
improving stage of diagnosis or mortality for OC. A recent
meta-analysis of randomised controlled trials found that
OC screening did not reduce mortality or the proportion of
advanced stage diagnosis [3]. However the largest ran-
domised controlled trial to date, the United Kingdom
Collaborative Trial of Ovarian Cancer Screening (UKC-
TOCS) has yet to report. Differences between UKCTOCS
and other OC screening trials may ultimately lead to the
demonstration of a mortality benefit [4], but currently
population-based OC screening is not recommended for
asymptomatic women at average risk of the disease,
although it may be part of the management plan for women
at high risk [5]. Future screening approaches would benefit
from identifying women who are at greatest risk of
developing OC and targeting screening to this group [6, 7].
With the advent of next generation sequencing and the
results of genome-wide association studies, knowledge of
B. Rahman  L. Fraser  L. Side  S. Gessler  A. Lanceley (&)
Department of Women’s Cancer, EGA Institute for Women’s
Health, University College London, London, UK
e-mail: a.lanceley@ucl.ac.uk
S. F. Meisel  J. Wardle
Department of Epidemiology and Public Health, Health
Behaviour Research Centre, University College London,
London, UK
123
Familial Cancer (2015) 14:135–144
DOI 10.1007/s10689-014-9769-5
the genetic basis of disease susceptibility is rapidly
expanding. There is potential to use this knowledge to
classify individuals by their genetic risk for a particular
disease [8]. This risk stratification approach could be
applied to cancer screening. A population-based program
for ovarian cancer risk prediction and stratification
(PROMISE 2016 ‘Predicting Risk of Ovarian Malignan-
cies, Improved Screening and Early detection) is under
investigation. This program will develop and validate
models for risk stratification, early detection and diagnosis
of OC which incorporate clinical, epidemiological, pro-
teomic and genetic data. These models will be used to
predict each woman’s risk of OC, aiming to improve out-
comes of the disease through prevention, screening and
early detection. Although the program is still in the early
stages of development and will be guided by our research,
we present some details of the program below.
For model development, genetic data will involve
genetic testing of high penetrance genes associated with
hereditary breast and ovarian cancer, BRCA1 and BRCA2,
as well as lower penetrance genes associated with ovarian
cancer susceptibility, BRIP1, RAD51C and RAD51D [9–
11]. Given the 10 % risk of ovarian cancer associated with
Lynch syndrome [12], mismatch repair genes MLH1,
MSH2, MSH6 and PMS2 will be included. Ongoing
genotyping and genetic association studies are likely to
yield other relevant genes and SNPs that could also be
incorporated. Clinical and epidemiological data will
include family history, environmental, hormonal and
reproductive factors. For early detection and diagnosis,
proteomic data will be used to improve current models of
ovarian cancer screening and diagnosis.
This approach to OC risk stratification means women
participating in the program will receive an estimation of
OC risk and be categorised into one of three risk groups—
low, intermediate or high. Thresholds for predicted risk for
categorising individuals into a risk group will be based on
retrospectively and prospectively validated models.
Women will be offered risk-stratified information, support
and risk management options. Some women at high risk
may also be offered prophylactic measures such as bilateral
salpingo-oophorectomy (BSO) to reduce their risk of OC.
All women greater than 18 years of age will be eligible to
participate; exclusion criteria includes previous oophorec-
tomy, past history of tubal, ovarian cancer or primary
peritoneal cancer, or personal history of genetic testing for
ovarian cancer predisposing genes.
The feasibility of risk-stratified cancer screening is
increasingly being explored, including the practicalities of
implementation. The Collaborative Oncological Gene-
environment Study (COGS) investigated the efficacy and
cost-effectiveness of stratified screening for cancer using
genomic information [13]. Through breast and prostate
cancer modelling, personalised screening using age and
polygenic risk detected the majority of cancers, while
reducing the number of people screened. Although this
report provides evidence for the potential benefits of risk-
stratified screening, it also identifies the need for further
research. Aside from the cost-effectiveness, utility, social
and legal implications the COGS report identifies a ‘critical
factor’ in the future introduction of risk-stratified screen-
ing, questioning whether ‘targeting resources according to
risk is seen as compatible with the interests of the entire
screening population’ (page 3). Given the novelty of a
population-based risk prediction and stratification program
for OC, there is a dearth of literature on this topic.
A Dutch study explored women’s attitudes towards
genetic testing for breast cancer susceptibility with the aim
of tailoring disease prevention strategies [14]. In general
women had positive attitudes towards a breast cancer
screening program based on genetic risk profile. This
included genetic susceptibility testing prior to screening, as
long as women who wanted to access screening were still
able to do so despite being at low genetic risk. A number of
issues were also raised around genetic testing, including
personal autonomy, managing test results, potential dis-
crimination and financial concerns relating to the cost of
testing.
As part of the OC risk prediction and stratification
program, we have begun to explore the opinions of the
‘entire screening population’. In an earlier focus group
study we explored attitudes to PROMISE 2016 in women
from the general population [15]. Like Henneman et al’s
findings [14], participants expressed strong support overall
for the proposed program, believing genetic testing for OC
risk and subsequent stratified screening would be highly
beneficial. However knowledge about OC and associated
risk factors was consistently low. Risk perception for OC
was also low and largely attributed to not having previ-
ously considered OC as a personal health threat. In con-
trast, there was awareness from all participants of the role
genetics play in the development of cancer and the
potential of genetic testing for OC risk was generally
embraced. Knowledge about OC risk was seen as
empowering, leading to possible preventive measures to
‘prepare for the future’. The concept of risk-stratified
screening was also met with enthusiasm, although some
concern was expressed that frequent OC screening for
women identified at high risk may cause anxiety. For
women identified at low risk, where screening would not be
advised, a few participants expressed the desire for
screening to be available on request, similar to the findings
of Henneman et al.
Building on the results of our focus group study and the
recommendations of the COGS report, this study explored
the attitudes of women at high risk of OC to the idea of a
136 B. Rahman et al.
123
population-based OC risk prediction and risk stratification
program. With their greater knowledge and experience of
OC, it was anticipated these women may offer insight into
the acceptability and potential impact of taking part in the
program. As the program is likely to identify a small
number of women at high risk of developing OC, identi-
fying the support and information needs to help women
understand and adjust to their higher risk status is vital.
Methods
Sample
Ethical approval was obtained from the University College
London Ethics Committee for non-NHS Research (project
ID 3162/001). Women at high risk of OC, either due to a
strong family history consistent with hereditary breast and
ovarian cancer or BRCA1/2 mutation carrier status, were
recruited to the study. As the aim of the program is early
detection and prevention, only women without a personal
history of cancer were invited. An invitation to participate
in this qualitative study was placed on two UK ovarian
cancer charity websites, The Eve Appeal and Ovacome
(http://www.eveappeal.org.uk/; http://www.ovacome.org.
uk/). Women interested in being interviewed were invited
to contact the research team directly to find out more about
the study.
Procedure
Women who contacted the research team were sent a
detailed information sheet. Interviews were conducted in
person or by telephone depending on the woman’s pref-
erence. Ten women participated in one-on-one, in-depth,
semi-structured interviews. An interview guide was used,
leaving wording and sequence of topics open and with
probes to elicit more information if needed. The discussion
topics included: experiences of learning of OC ‘high risk’,
risk perceptions, OC knowledge and awareness, opinions
on risk stratification and opinions on risk management
options. An explanation of the risk stratification approach
and risk management options was given to participants
(Table 1). Interviews were digitally recorded and tran-
scribed verbatim. Participants also completed a consent
form, brief demographic questionnaire and cancer family
history form. Data for two of the 10 women interviewed
were excluded because it was established during the
interview that one had a diagnosis of breast cancer, and one
had previously had predictive BRCA1/2 testing and
received a negative result.
Data analysis
Thematic analysis was used to analyse the interview tran-
scripts. This method identifies, analyses and reports pat-
terns or themes within the data [16]. The process of
analysis involved several stages, beginning by reviewing
the data and noting initial ideas. Once familiarised with the
data, initial codes were then generated in a systematic
manner for the entire data set. Codes were collated into
potential themes, where similar but separate codes were
combined and refined. Themes were reviewed, refined and
organised into a final theme list. Transcripts were coded by
BR using the qualitative data analysis software QSR NVivo
10. To increase rigour all transcripts were also coded by
another member of the research team (SM); any differences
were discussed until agreement was reached.
Results
Participants were aged between 25 and 58 years, and had a
variety of experiences in terms of genetic testing, risk-
reducing surgery and OC screening (Table 2). All had a
family history of at least one first degree relative with OC
Table 1 Information provided to participants on risk stratification and risk management options
Opinions on a risk prediction program using risk stratification approach
Risk stratification means that women can be grouped based on their likelihood of getting ovarian cancer. Women can be described as having a
low, intermediate or high risk. The level of risk is based on a woman’s genetic risk and other risk factors. Identifying genetic risk involves
having a blood test. Identifying other risk factors would involve filling in questionnaires about cancer family history, background and health
information. Scientists can then put all of this information together and estimate whether a women is at low, intermediate or high risk. It is
estimated that 50–60 % of women will be at low risk, 30–45 % at intermediate risk, and 4–7 % at high risk
Opinions on possible risk management options
Depending on a woman’s risk level (low, intermediate or high), she would receive different levels of risk management for ovarian cancer.
Women at low risk would receive information telling them that they are at low risk and that they do not need further monitoring. This
information would also let low-risk individuals know about symptoms of ovarian cancer. Women at intermediate risk would receive screening
every year (screening involves a blood test to check for levels of the biomarker CA-125 followed by transvaginal ultrasound). Those at high
risk would be screened every 4 months. High-risk women may also be referred to a specialist to discuss risk-reducing surgery
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or multiple first and second degree relatives with breast
cancer and/or OC.
Ovarian cancer perceptions
OC was often described by participants as an ‘unknown’
disease. Prior to the diagnoses in their family, participants
had little or no knowledge about OC or possible risk fac-
tors. For the participants who were BRCA1/2 mutation
carriers with a family history of breast cancer, the risk of
OC was not known until it was disclosed during the genetic
testing and counselling process. Learning about OC risks
was unexpected, with these participants describing the
experience as a ‘shock’ or ‘surprise’.
So yeah, hearing that I did have that risk, like I said,
that was quite a shock to me. I hadn’t really linked
the two, I guess because we didn’t know for a while
that it was a genetic thing. I always thought it was
breast cancer that came my way. I didn’t realise that I
was such high risk for ovarian. (HROC_05)
Coupled with the lack of information available in the general
community, participants were also fearful of OC. This was
exacerbated by the lack of effective methods to detect the
cancer; giving the impression that OC is an ‘invisible’
disease which may not be identified until an advanced stage
due to the vague symptoms associated with OC such as
bloating and pelvic or abdominal pain. When compared to
breast cancer, participants felt OC was a more complex and
worrying disease. Despite BRCA1/2 carriers being at higher
relative risk for breast cancer (up to 80 %) compared to OC
(with risks of up to 40 %) [17], participants felt less
concerned about breast cancer because they perceived there
was greater awareness about the disease, and early detection
and screening methods were more effective.
I think also, as well, there is so much more infor-
mation out there about breast cancer that it doesn’t
frighten me as much, I think because it is more easily
detectable. I think the whole thing about the potential
for an ovarian tumour, the whole thing that frightened
me so much about it was that it is so hard to detect.
You know, it is not something that would show up on
a smear, you wouldn’t necessarily have lumps pro-
truding from your stomach, it is very, very difficult to
detect it and I think that was a big part of the fear
factor for me, was I could have this, I could already
have this and it would be relatively well advanced
and I wouldn’t necessarily know, you know. Whereas
in the case of breasts, you know, if you are doing the
checks, you are going to find a lump. (HROC_02)
Attitudes towards PROMISE 2016
There was a strong positive response to the idea of a
population-based risk prediction and stratification program.
Participants felt the main benefit of the program would be
to provide accurate information and support regarding OC
risks, either by reassuring women who mistakenly believed
they were at increased risk or by providing effective clin-
ical interventions (surgery/screening) for those who were in
fact at increased risk. The program would also play a key
role in raising women’s awareness about the disease.
I think if you are looking around your family and
thinking there’s so many cancers, you know, what
have I got, what am I going to get, I think it might
also be a reassurance that no, these are just really bad
luck and it’s not necessarily something that’s destined
to come your way. It could be quite a good reassur-
ance for people whose risks they perceive to be
higher than they actually are. (HROC_05)
There were varying opinions on how the program would be
received by the female population. A number of partici-
pants felt that the majority of eligible women would be
interested and willing to be involved in the program to
learn their risk for OC, but others felt that interest and
motivation would be low given the lack of awareness about
OC and associated risk factors. Participants felt that a
family history of cancer or existing worries about devel-
oping OC would motivate participation.
The idea of women being stratified into low and high
risk OC groups was well received. Participants felt that
Table 2 Participant characteristics (n = 8)
Participant Age Genetic
testing
Genetic
testing
result
Risk-
reducing
surgery
Screening
BSO Mx
HROC_02 38 No – Yes No No
HROC_03 42 Yes No
mutation
Yes No No
HROC_04 45 Yes No
mutation
Yes No Yes—until
BSO
HROC_05 35 Yes BRCA2
?ve
No Yes Yes
HROC_06 37 Yes BRCA1
?ve
No No No
HROC_07 58 No – No No Yes
HROC_08 29 Yes BRCA1
?ve
No No No
HROC_10 25 Yes BRCA1
?ve
No Yes No
BSO = bilateral salpingo-oophorectomy, Mx = mastectomy,
Screening = transvaginal ultrasound and/or CA125 biomarker,
?ve = mutation positive
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women in the low risk group would experience a sense of
relief, particularly if they had anticipated being at higher
risk for OC. For women identified as being in the high risk
group, knowing this information and having regular
screening or testing was seen as reassuring, with surveil-
lance for early detection acting as a safety net. The concept
of an intermediate risk group was met with some hesitancy
by the participants. A number of women were unsure of
what benefit having this information would provide. The
perception was that individuals in this risk category may be
concerned at being at increased risk compared to the low
risk group, but without being offered the surveillance or
prevention options available to those in the high risk group.
That’s the thing. If you are high risk, also, then you
can then go down my route. If you are low risk you
are just becoming more aware of just general health
issues. But if you are intermediate I don’t know what
the benefit would be to know really because you
wouldn’t necessary get the… well, I don’t know,
maybe you would. Would you go and have a hys-
terectomy? I don’t know. That would be my question.
(HROC_06)
In terms of the suggested screening and interventions for
the risk-stratified groups, participants felt that for the low
risk group receiving information about OC, in particular
potential symptoms, was sufficient. Interest in annual and
4-monthly screening, respectively, for the intermediate and
high risk groups was tempered by concerns about the
efficacy of screening.
Knowledge and information
Knowledge was seen as learning about genetic risks for OC
through genetic testing or assessment of family history,
culminating in receiving a risk estimate of developing the
disease. Participants were unanimous in their desire to have
this information, describing knowledge as power. They
also felt strongly that this knowledge should be used to take
action and reduce their risk of developing cancer; an
opportunity that other family members had not had.
Gosh, I mean, I had the option before I went for the
genetic test, obviously, not to go for it, but, for me,
no, I wanted to know. It was forewarned is fore-
armed. I can do something about it. (HROC_05)
Given this desire for knowledge, participants insisted that
the risk prediction program must provide information not
only regarding the risk-management aspect of the program,
but about OC itself. In their previous experiences they had
struggled to find accurate and reliable information regard-
ing risk factors, symptoms, screening and preventive
options. As a result participants described wanting as
much information as possible. They felt this information
would need to be an integral part of the risk prediction
program to allow women in the population to make an
informed decision about participation in the program.
If you know what you are looking out for, you know,
it could be that you do actually just have IBS, but
equally, you might not and I think the more women
know and the more information they have, they can
make the rational decisions themselves about do I
need to seek medical help here or, you know, can I
maybe leave it a little while and see if simple anal-
gesia and a hot water bottle makes me feel better? But
I think the more information people have, by far and
away the better. (HROC_02)
Risk communication
The participants who had previously had genetic testing
and genetic counselling and been found to carry a BRCA1/
2 mutation recalled receiving risk estimates for breast
cancer and OC described as a percentage risk. In general
this format was well received, being described as easily
understood and interpreted. They were also provided with
age-related risks, a specific age or age range at which OC
risk becomes significant. Age-related risk information was
perceived as very helpful—participants described being
able to compartmentalise their risk until they reached their
‘at-risk age’, deferring their cancer worries to a specific
time in the future. Those who had less formal risk assess-
ment recalled their risk described as ‘10 times higher than
the general population’, or a ‘1 in 8’ chance of developing
OC.
I am not saying it’s right or wrong, but I have always
been told, ‘‘You don’t need it. You just need to know
your at-risk age. You have got the gene. You are high
risk, we know that. We need to work out your at-risk
age category.’’ So, for me, it’s, like, it’s very early
40s and that’s what I have always worked on.
(HROC_06)
Participants had many suggestions about how risk esti-
mates should be communicated in the OC risk prediction
and stratification program such as numeric risk estimates,
preferably percentages, and descriptive estimates. Com-
parisons to general population risks were recommended to
help women put their risk in perspective. The challenge of
using only one risk format for a large diverse female
population was acknowledged and reflected in the lack of
consensus about what the preferred format should be.
There was agreement that the ‘higher’ risk estimates such
as 1 in 10 would be more meaningful than trying to
interpret ‘lower’ risks such as 1 in 1,000 or 1 %. Clear
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distinctions in risk estimates between the three risk
groups—high, intermediate and low—would be important
so that women would be aware of not only their risk
estimate but also risk ‘classification’.
Because if you are 1 in a 1,000 and you are low risk,
it does sound, oh, it’s never going to happen to me,
it’s never going to happen to the 1 in a 1,000, it’s
never going to happen to me. Whereas if you are
intermediate risk then it needs to be a bit more clear
that, you know, it is a higher risk. (HROC_06)
Psychological support
The interviews showed that participants employed indi-
vidual strategies to cope with their high risk status. For
some, there was a sense of wanting to do as much as
possible to reduce their cancer risk, either through surgery
or screening. Participants who had undergone risk-reducing
surgery (either mastectomy or oophorectomy) felt reas-
sured that their cancer risks had been reduced by their
actions, despite any complications from surgery and the
challenges of managing menopausal symptoms.
I just have to turn it into a positive thing and, you
know, even the normal, you know, people without the
gene have got a higher risk than me now. So it’s a
good thing and something that my mum and the rest
of the family couldn’t have done. (HROC_10)
Other participants who had not undergone BSO described
the importance of not dwelling on OC risks; while they
acknowledged that risks remain, rumination was not seen
as a helpful strategy.
The things that I can do, I have done, but I am not
prepared at the moment to think about the option of
surgery again until it becomes a greater risk… I feel
like I have done what I can at the moment but I don’t
want to, kind of, tie myself up in mental knots by
having to think about it too much now. I am doing all
I can realistically, I think. (HROC_05)
It was encouraging that the participants in this study were
able to use different coping strategies to manage their high
risk status. Although the risks remain ‘at the back of the
mind’, they were able to continue their lives. Given the
psychological burden most women at high risk for OC may
face, it is not surprising that all participants spoke about the
need for psychological and emotional support to be
provided within the program. Ideally support would be
available before and after receiving OC risk estimates, with
a preference for face-to-face interactions with either a
psychologist or genetic counsellor.
It is, and I think based on my own experiences and
going by what I could have done with and didn’t have
access to, I think for women at all levels of risk, the
one thing I would say would be ensure that there is
some form of emotional support, even if, as part of
the study, you made it mandatory. (HROC_02)
Interactions with health professionals
Interactions with health professionals (HPs) were an inte-
gral part of all participants’ narratives of their OC experi-
ences. Interactions with General Practitioners (GPs) were
often described as particularly distressing, with missed or
delayed diagnoses attributed to the GPs lack of interest in,
or knowledge of, OC. GPs were often perceived as barriers
to further investigations or referral to specialists. Some
women described the ‘battle’ they faced for requests to see
a gynaecologist or for CA-125 testing. There was also
sense of paternalism embedded within the interactions—
women were told ‘not to worry’ and their symptoms were
often dismissed as overreactions. There is clearly a need
for better training and education for health professionals, in
particular GPs, about OC.
But it does come down to a doctor in a lot of ways but
I think it’s the GPs often because that the first port of
call before you even get to there. I mean, my mother
must have gone to a GP many times before she got to
see a consultant, many times, many, many, many
times. So it’s the GPs, really, who can be a stumbling
block and it’s often about…What I feel personally, is
there’s a lot of emphasis on things like heart disease
and diabetes and obesity and the, kind of, women
issues tend to get just […dismissed]. (HROC_04)
Discussion
The prospect of genetic risk stratification to inform
screening programs is becoming increasingly viable given
the advances in genetic technology. Like our earlier focus
group study with women from the general population [15],
women at high risk for OC had positive attitudes towards
the idea of a population-based risk prediction and stratifi-
cation program. It is encouraging that women with differ-
ent experiences and knowledge of OC are supportive of the
program.
Although the proposed program was well received, there
was a lack of consensus amongst participants in how they
felt it would be received by the general population. Some
felt the main motivating factor for uptake would be pre-
existing worry for cancer, perhaps reflecting their own
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perspectives of being at high risk for OC. The influence of
cancer worry has previously been described in the cancer
screening and genetic testing literature. Women who
accept predictive BRCA1/2 genetic testing tend to have
significantly higher levels of cancer worry than women
who decline testing [17]. Cancer worry also plays a role in
cancer screening behaviours; a review by Hay concluded
that participation in cancer screening is facilitated by
cancer worry both for individuals from the general popu-
lation as well as those at high risk of cancer [18]. This has
important implications for the potential implementation of
the program. Existing national cancer screening programs
such as mammography for breast cancer show that uptake
by eligible women in the UK is relatively high at 73 %
[16]. Although stratified screening would be expected to
reduce the overall number of people who have screening by
targeting those at greatest risk, it may in fact increase
uptake by those who are eligible. The question remains
whether providing genetic information about risk of cancer
development will increase participation and adherence to a
screening program.
The majority of participants felt the main benefit of the
program would be to (1) provide reassurance for women
classified into the low risk group and (2) reduce worry for
women at high risk who could be appropriately managed
with risk-reducing surgery or regular screening. Implicit in
this belief is that women who participate in the program
will feel, to some degree, at risk for OC. However a survey
of OC risk perceptions among women participating in the
UKCTOCS trial found that around 40 % of women accu-
rately estimated their lifetime risk of developing OC,
around 50 % underestimated their risk, while less than
10 % overestimated the risk [18]. Similar estimates of risk
were found in a large-scale survey of Australian women
[19]. In general it seems women from the general popu-
lation have accurate or lower perceptions of risk regarding
OC development in their lifetime. There is a tendency for
individuals to believe they are less at risk compared to their
peers to a range of risks, including health risks. Termed
unrealistic optimism by Weinstein, it may explain some of
the optimistic bias seen in OC risk estimations [20]. In
contrast, previous studies have shown that a significant
proportion of women at increased OC risk due to family
history or BRCA1/2 mutation overestimate their risk [21,
22]. The reassurance described by participants may be most
effective for the small group of women overestimating
their risk of OC and those identified at high risk.
Participants also felt a significant benefit of the program
would be to raise awareness about OC. A number of
studies, including the earlier focus group work, have
identified low awareness of OC symptoms and risk factors
in women in the general population [15, 19, 23]. Partici-
pants in the current study described their own lack of
knowledge regarding OC symptoms, and their struggle to
find accurate and appropriate information. They felt that a
large scale effort is needed to educate the public about OC,
so it becomes integrated into the ‘female psyche’ as has
been the case for breast cancer.
A significant part of PROMISE 2016 will involve the
communication of OC risk estimates to the public. In this
study we referred to three risk categories—low, interme-
diate and high—that may be used for risk stratification. It
has been suggested that the risk information communicated
was simplified by participants with only the ‘gist’ of the
information being recalled, i.e. ‘low risk’ versus ‘high risk’
and therefore the ‘intermediate risk’ is ignored [24]. A
binary understanding of risk, e.g. something will or will not
happen, or low vs high risk, has also been described in the
genetic counselling literature as a response to receiving
genetic risk information [25]. This was reflected in the
current study, as one high risk participant said, ‘Because
even me, I think I am 65 % risk and although that is high,
in a way it almost doesn’t sound high because it almost
sounds like, oh well, it’s almost 50/500. Another participant
commented, ‘You see, and the other thing about risk is, in
the end it doesn’t matter what the percentage is or what
your chance is, what the risk is… You know, you can’t get
10 % of ovarian cancer. You either get it or you don’t.’
Given the responses of women at high risk to the proposed
intermediate risk category, coupled with the lack of interest
in the lower risk categories by participants in the focus
group, the planned approach to risk categorisation may
need to be modified. Using a binary approach for risk
stratification may be more suitable. For example two cat-
egories of lower and higher risks to differentiate between
women with risk estimates low enough not to warrant
further worry about OC (outcome: reassurance) and those
with estimates high enough to be under surveillance (out-
come: screening).
Methods for communicating the individual estimates of
OC risk also need to be considered. Despite the preference
for receiving risk information as a percentage risk, studies
have shown that people struggle to understand numerical
probability statistics, with comprehension and interpreta-
tion influenced by their level of numeracy [26]. However
verbal expressions to convey probabilities can be inter-
preted too subjectively [27]. The importance of effective
risk communication cannot be underestimated; studies
have shown that risk perception is a better predictor of
behaviour rather than the actual risk communicated [28].
There is evidence that risk perceptions can influence
screening behaviours and medical decisions [29, 30]. In the
present study, some participants indicated a preference for
estimates presented as percentages or proportions, while
others felt concerned that providing a numeric risk would
be frightening and preferred descriptions or comparisons to
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the general population. These results highlight individual
preferences for receiving genetic risk information. Devel-
oping formats of communicating risk estimates that are
well received and comprehensible to a large and varied
population is a key issue for the successful implementation
of the program.
Fear of OC, attributed to its ‘unknown’ and invisible
nature was often described by participants. They felt non-
specific OC symptoms made it difficult to identify which
are ‘real’ symptoms that should be investigated further,
leading to diagnostic delay [31–33]. Delays were a prom-
inent theme in the interviews, with numerous descriptions
of the difficulties participants faced in their interactions
with health professionals, in particular the GPs responsible
for their own or their relative’s care. These experiences
were distressing and it seems that these challenging inter-
actions are not uncommon in women at high risk for OC
[34]. Delays experienced by British women in obtaining an
OC diagnosis are also compounded by doctor or health
service delays [32]. Raising awareness about OC is not
only important in the general population, but also within
the medical profession. Future research regarding this
program needs to consider approaches to improving inter-
actions between providers and patients, as well as educa-
tion programs targeted at GPs.
Despite clinical advances in understanding the patho-
genesis of OC and development of targeted treatments,
outcomes remain poor. Current OC screening involving
CA125 biomarkers and transvaginal ultrasound have not
yet shown sufficient sensitivity or specificity to be used
clinically. Research now turns to novel methods of early
detection and prevention. By combining increasing
knowledge on underlying genetic susceptibility of OC,
biomarker discovery and validation, modelling and health
behaviour research, PROMISE 2016 endeavours to trans-
late these advances into a population-based intervention.
Although the program is at an early stage of development,
risk stratification for OC has the potential to reduce the
number of OC diagnoses by identifying women at high risk
and offering risk-reducing management options. When
high risk of OC is due to carrying a highly penetrant gene
mutation, identification of this risk benefits not only the
woman who participates, but may also have a cascade
effect for at-risk relatives. From a screening perspec-
tive, until data from UKCTOCS are reported it is difficult
to comment on the benefit of identifying women at
increased risk, however advances in proteomics are being
used to develop accurate biomarkers capable of signifi-
cantly improving early detection and diagnosis. The
response of participants to the proposed intermediate risk
group in this study was invaluable for our understanding of
perceived utility of risk categorisation, and will influence
the development and implementation of the program in the
future.
Limitations
We acknowledge that this is a small study involving eight
participants and is by no means an exhaustive exploration
of the topic. There was a variety of opinions and experi-
ences across the participants, but there was also consensus
in support for and attitudes towards the risk prediction and
stratification program. This level of thematic representation
across the data set is entirely acceptable according to Braun
and Clark [16]. Recruiting women to participate from the
‘public’ setting through OC charity websites, and not from
a hereditary cancer clinic, proved more challenging than
anticipated. It may have been that the majority of women
who access the websites have already been affected by
cancer, which was the only exclusion criterion of this
study.
Conclusion
What is clear from these eight interviews is that the process
of learning about OC risk is a long and often fraught
journey. Many women had witnessed their close relatives
suffer and, in most cases, eventually succumb to the dis-
ease. Barriers between them and their health professionals
meant participants felt they struggled for their OC concerns
to be acknowledged and addressed. Despite variation in
age, family history and OC experiences of the participants,
there was strong consensus amongst the group that a
population-based risk prediction, stratification and screen-
ing program for OC should be introduced. The main
anticipated benefit was the relief and reassurance it would
provide to the majority of the population who would be
classified at low risk for developing OC. The call for more
information regarding OC as well as the provision of
psychological and emotional support, and the need for this
to be provided by PROMISE 2016 was highly informative.
The lack of consensus for how to communicate OC risk
estimates to the public clearly indicated the need for more
research in this area.
Although these results are encouraging, the task now
turns to exploring the logistics of program implementation
where uptake rates for genetic testing are known to be
significantly lower than reported interest and intention
levels [35–37]. This preliminary stage of research involves
exploratory work with stakeholders, in this case the ‘entire
screening population’, to learn their views and attitudes
towards the proposed program. To further our under-
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standing of attitudes and acceptability, interviews with
another key group of stakeholders, health professionals,
will also be undertaken.
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